SRR6079986
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.590
- MYC_TARGETS_V1+0.500
- G2M_CHECKPOINT+0.420
- MYC_TARGETS_V2+0.360
- OXIDATIVE_PHOSPHORYLATION+0.360
- DNA_REPAIR+0.270
- FATTY_ACID_METABOLISM+0.220
- PEROXISOME+0.150
- WNT_BETA_CATENIN_SIGNALING+0.140
- ESTROGEN_RESPONSE_LATE+0.130
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.460
- ALLOGRAFT_REJECTION-0.400
- INFLAMMATORY_RESPONSE-0.400
- COAGULATION-0.360
- HYPOXIA-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- IL6_JAK_STAT3_SIGNALING-0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- TGF_BETA_SIGNALING-0.340
- IL2_STAT5_SIGNALING-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-01285 | — | cohortSQ2 | 0.864 |
| 2 | BS_53M8PP88 | EPN | EPN Tumor | 0.861 |
| 3 | SRR4195654 | — | — | 0.860 |
| 4 | fea46737-a2b3-49d4-8358-d0737546b6da | — | — | 0.850 |
| 5 | C3L-00993 | — | cohortSQ1 | 0.846 |
| 6 | 3d1f89ec-ac0b-40f8-ac89-ed0c2d4967b7 | — | — | 0.844 |
| 7 | SAMN03290897 | — | — | 0.840 |
| 8 | BS_53M8PP88 | Ependymoma NOS | — | 0.840 |
| 9 | TCGA-44-7667-01A-31R-2066-07 | — | cohortA3 | 0.839 |
| 10 | TCGA-UY-A78N-01A-12R-A33J-07 | — | — | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.010 | Inavolisib | — uncovered |